UNSPSC 51434500: Antihypertensive tetrazoles

Antihypertensive drugs made from 5-member ring of four nitrogen atom and one carbon atom, based on CN4H2.

UNSPSC 51434500 Antihypertensive tetrazoles is a Class code encompassing pharmaceutical preparations used to manage hypertension, specifically tetrazole-based compounds supplied to state and local public health and emergency services organizations. State and local governments procure these medications for use by fire rescue departments, emergency medical services, and health and human services agencies, often as part of broader advanced life support medication programs or pharmacy benefit initiatives. Issuing bodies include municipal fire departments and emergency services (such as Tampa Fire Rescue), state health and human services agencies (such as the Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving state and local facilities. The code shows activity across multiple procurement vehicles, including sealed bid solicitations for immediate medication supply, requests for information to explore direct-to-manufacturer pharmacy programs, and cooperative purchasing agreements administered through established wholesaler networks.

Geographic activity centers on Florida and Texas in the most recent opportunities, with Texas using exploratory procurement mechanisms to develop direct-to-manufacturer pharmaceutical supply models. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including antihypertensive agents such as Labetalol HCl 100 mg vials and Diltiazem 25 mg vials, with a bid deadline of April 8, 2026, and an estimated contract value of $40,000, featuring a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, requiring vendor pricing through authorized wholesalers with contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission issued an RFI on March 27, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities without naming a formal timeline or budget allocation, indicating exploratory activity at the state level to reshape pharmacy benefit procurement.